|
1
|
Kossai M, Leary A, Scoazec JY and Genestie
C: Ovarian cancer: A heterogeneous disease. Pathobiology. 85:41–49.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kroeger PT and Drapkin R: Pathogenesis and
heterogeneity in ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Labrie M, De Araujo LOF, Communal L,
Mes-Masson AM and St-Pierre Y: Tissue and plasma levels of
galectins in patients with high grade serous ovarian carcinoma as
new predictive biomarkers. Sci Rep. 7:13242017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dubé-Delarosbil C and St-Pierre Y: The
emerging role of galectins in high-fatality cancers. Cell Mol Life
Sci. 75:1215–1226. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Compagno D, Gentilini LD, Jaworski FM,
Pérez IG, Contrufo G and Laderach DJ: Glycans and galectins in
prostate cancer biology, angiogenesis and metastasis. Glycobiology.
24:899–906. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thijssen VL, Rabinovich GA and Griffioen
AW: Vascular galectins: Regulators of tumor progression and targets
for cancer therapy. Cytokine Growth Factor Rev. 24:547–558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dings RP, Miller MC, Griffin RJ and Mayo
KH: Galectins as molecular targets for therapeutic intervention.
Int J Mol Sci. 19:905–927. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wdowiak K, Francuz T, Gallego-Colon E,
Ruiz-Agamez N, Kubeczko M, Grochoła I and Wojnar J: Galectin
targeted therapy in oncology: Current knowledge and perspectives.
Int J Mol Sci. 19:210–231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balan V, Nangia-Makker P and Raz A:
Galectins as cancer biomarkers. Cancers (Basel). 2:592–610. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rabinovich GA, Baum LG, Tinari N,
Paganelli R, Natoli C, Liu FT and Iacobelli S: Galectins and their
ligands: Amplifiers, silencers or tuners of the inflammatory
response? Trends Immunol. 23:313–320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Camby I, Le Mercier M, Lefranc F and Kiss
R: Galectin-1: A small protein with major functions. Glycobiology.
16:137R–157R. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu MH, Hong TM, Cheng HW, Pan SH, Liang
YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, et al:
Galectin-1-mediated tumor invasion and metastasis, up-regulated
matrix metalloproteinase expression, and reorganized actin
cytoskeletons. Mol Cancer Res. 7:311–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anginot A, Espeli M, Chasson L, Mancini SJ
and Schiff C: Galectin1 modulates plasma cell homeostasis and
regulates the humoral immune response. J Immunol. 190:5526–5533.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sandberg TP, Oosting J, van Pelt G, Mesker
WE, Tollenaar RAEM and Morreau H: Molecular profiling of colorectal
tumors stratified by the histological tumor-stroma ratio-increased
expression of galectin-1 in tumors with high stromal content.
Oncotarget. 9:31502–31515. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Satelli A, Rao PS, Gupta PK, Lockman PR,
Srivenugopal KS and Rao US: Varied expression and localization of
multiple galectins in different cancer cell lines. Oncol Rep.
19:587–594. 2008.PubMed/NCBI
|
|
16
|
Hughes RC: Secretion of the galectin
family of mammalian carbohydrate-binding proteins. Biochim Biophys
Acta. 1473:172–185. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sundblad V, Morosi LG, Geffner JR and
Rabinovich GA: Galectin-1: A Jack-of-All-Trades in the resolution
of acute and chronic inflammation. J Immunol. 199:3721–3730. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perillo NL, Pace KE, Seilhamer JJ and Baum
LG: Apoptosis of T cells mediated by galectin-1. Nature.
378:736–739. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rabinovich GA, Iglesias MM, Modesti NM,
Castagna LF, Wolfenstein-Todel C, Riera CM and Sotomayor CE:
Activated rat macrophages produce a galectin-1-like protein that
induces apoptosis of T cells: Biochemical and functional
characterization. J Immunol. 160:4831–4840. 1998.PubMed/NCBI
|
|
20
|
Matarrese P, Tinari A, Mormone E, Bianco
GA, Toscano MA, Ascione B, Rabinovich GA and Malorni W: Galectin-1
sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell
death via mitochondrial hyperpolarization, budding, and fission. J
Biol Chem. 280:6969–6985. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dias-Baruffi M, Zhu H, Cho M, Karmakar S,
McEver RP and Cummings RD: Dimeric galectin-1 induces surface
exposure of phosphatidylserine and phagocytic recognition of
leukocytes without inducing apoptosis. J Biol Chem.
278:41282–41293. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stowell SR, Karmakar S, Stowell CJ,
Dias-Baruffi M, McEver RP and Cummings RD: Human galectins-1, −2,
and −4 induce surface exposure of phosphatidylserine in activated
human neutrophils but not in activated T cells. Blood. 109:219–227.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hernandez JD and Baum LG: Ah, sweet
mystery of death! Galectins and control of cell fate. Glycobiology.
12:127–136. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sturm A, Lensch M and Andre S: Human
galectin-2: Novel inducer of T cell apoptosis with distinct profile
of caspase activation. J Immunol. 173:3825–3837. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fuertes MB, Molinero LL, Toscano MA,
Ilarregui JM, Rubinstein N, Fainboim L, Zwirner NW and Rabinovich
GA: Regulated expression of galectin-1 during T-cell activation
involves Lck and Fyn kinases and signaling through MEK1/ERK, p38
MAP kinase and p70S6 kinase. Mol Cell Biochem. 267:177–185. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rubinstein N, Alvarez M, Zwirner NW,
Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer
OL and Rabinovich GA: Targeted inhibition of galectin-1 gene
expression in tumor cells results in heightened T cell-mediated
rejection: A potential mechanism of tumor-immune privilege. Cancer
Cell. 5:241–251. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Toscano MA, Commodaro AG, Ilarregui JM,
Bianco GA, Liberman A, Serra HM, Hirabayashi J, Rizzo LV and
Rabinovich GA: Galectin-1 suppresses autoimmune retinal disease by
promoting concomitant Th2- and T regulatory-mediated
anti-inflammatory responses. J Immunol. 176:6323–6332. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Toscano MA, Bianco GA, Ilarregui JM, Croci
DO, Correale J, Hernandez JD, Zwirner NW, Poirier F, Riley EM, Baum
LG and Rabinovich GA: Differential glycosylation of TH1, TH2 and
TH-17 effector cells selectively regulates susceptibility to cell
death. Nat Immunol. 8:825–834. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kuo PL, Huang MS, Cheng DE, Hung JY, Yang
CJ and Chou SH: Lung cancer-derived galectin-1 enhances tumorigenic
potentiation of tumor-associated dendritic cells by expressing
heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soldati R, Berger E, Zenclussen AC, Jorch
G, Lode HN, Salatino M, Rabinovich GA and Fest S: Neuroblastoma
triggers an immunoevasive program involving galectin-1-dependent
modulation of T cell and dendritic cell compartments. Int J Cancer.
131:1131–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ilarregui JM, Croci DO, Bianco GA, Toscano
MA, Salatino M, Vermeulen ME, Geffner JR and Rabinovich GA:
Tolerogenic signals delivered by dendritic cells to T cells through
a galectin-1-driven immunoregulatory circuit involving interleukin
27 and interleukin 10. Nat Immunol. 10:981–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cedeno-Laurent F, Opperman M, Barthel SR,
Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an
immunoregulatory signature in Th cells functionally defined by
IL-10 expression. J Immunol. 188:3127–3137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baatar D, Olkhanud PB, Wells V, Indig FE,
Mallucci L and Biragyn A: Tregs utilize beta-galactoside-binding
protein to transiently inhibit PI3K/p21ras activity of human
CD8+ T cells to block their TCR-mediated ERK activity
and proliferation. Brain Behav Immun. 23:1028–1037. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Garín MI, Chu CC, Golshayan D,
Cernuda-Morollón E, Wait R and Lechler RI: Galectin-1: A key
effector of regulation mediated by CD4+CD25+
T cells. Blood. 109:2058–2065. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Espeli M, Mancini SJ, Breton C, Poirier F
and Schiff C: Impaired B-cell development at the pre-BII-cell stage
in galectin-1-deficient mice due to inefficient pre-BII/stromal
cell interactions. Blood. 113:5878–5886. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mourcin F, Breton C, Tellier J, Narang P,
Chasson L, Jorquera A, Coles M, Schiff C and Mancini SJ:
Galectin-1-expressing stromal cells constitute a specific niche for
pre-BII cell development in mouse bone marrow. Blood.
117:6552–6561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsai CM, Chiu YK, Hsu TL, Lin IY, Hsieh SL
and Lin KI: Galectin-1 promotes immunoglobulin production during
plasma cell differentiation. J Immunol. 181:4570–4579. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen L, Yao Y, Sun L and Tang J:
Galectin-1 promotes tumor progression via NF-κB signaling pathway
in epithelial ovarian cancer. J Cancer. 8:3733–3741. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang P, Shi B, Zhou M, Jiang H, Zhang H,
Pan X, Gao H, Sun H and Li Z: Galectin-1 overexpression promotes
progression and chemoresistance to cisplatin in epithelial ovarian
cancer. Cell Death Dis. 5:e9912014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ,
Do IG, Song SY, Lee YY, Choi CH, Kim TJ, et al: High galectin-1
expression correlates with poor prognosis and is involved in
epithelial ovarian cancer proliferation and invasion. Eur J Cancer.
48:1914–1921. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schulz H, Schmoeckel E, Kuhn C, Hofmann S,
Mayr D, Mahner S and Jeschke U: Galectins-1, −3, and −7 are
prognostic markers for survival of ovarian cancer patients. Int J
Mol Sci. 18:12302017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen L, Yao Y, Sun L, Zhou J, Liu J, Wang
J, Li J and Tang J: Clinical implication of the serum galectin-1
expression in epithelial ovarian cancer patients. J Ovarian Res.
8:782015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abdelwahab M, Ebian H, Ibrahim T, Badr M,
Lashin M, Yassin M, Ismail A and Obaya A: Clinical significance of
serum galectin-1 and its tissue immunohistochemical expression in
serous ovarian carcinoma patients. J Obstet Gynecol. 9:937–953.
2019.
|
|
44
|
Argüeso P and Panjwani N: Focus on
molecules: Galectin-3. Exp Eye Res. 9:2–3. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pinnelli V, Sirsiker M and Silvia WD:
Galectin-3: A novel biomarker. Int J Chem Pharm Res. 2:81–94.
2013.
|
|
46
|
Lityńska A and Pokrywka M: Structure and
biological functions of galectin-3 Część Part I. Post Biol Kom.
37:677–684. 2010.
|
|
47
|
Pokrywka M and Lityńska A: Structure and
biological functions of galectin-3 Part II. Post Biol Kom.
37:685–697. 2010.
|
|
48
|
Ruvolo P: Galectin-3 as a guardian of the
tumor microenvironment. Biochim Biophys Acta. 1863:427–437. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gudowska M and Chrostek L: Diagnostic role
of galectin-3. Pol Merkur Lekarski. 222:408–412. 2014.(In Polish).
PubMed/NCBI
|
|
50
|
Li M, Feng YM and Fang SQ: Overexpression
of ezrin and galectin-3 as predictors of poor prognosis of cervical
cancer. Braz J Med Biol Res. 50:5356–5365. 2017. View Article : Google Scholar
|
|
51
|
Wdowiak K, Spychałowicz W, Fajkis M and
Wojnar J: Galectins in hematological malignancies-role, functions
and potential therapeutic targets. Postepy Hig Med Dosw (Online.
70:95–103. 2016.(In Polish). View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Punt S, Thijssen VL, Vrolijk J, de Kroon
CD, Gorter A and Jordanova E: Galectin-1, −3 and −9 expression and
clinical significance in squamous cervical cancer. PLoS One.
10:e01291192015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vladoiu MC, Labrie M and St-Pierre Y:
Intracellular galectins in cancer cells: Potential new targets for
therapy (Review). Int J Oncol. 44:1001–10014. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chetry M, Thapa S, Hu X, Song Y, Zhang J,
Zhu H and Zhu X: The role of galectins in tumor progression,
treatment and prognosis of gynecological cancers. J Cancer.
9:4742–4755. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang L, Zhao Y, Wang Y and Wu X: The role
of galectins in cervical cancer biology and progression. Biomed Res
Int. 2018:21759272018.PubMed/NCBI
|
|
56
|
Farhad M, Rolig A and Redmond W: The role
of Galectin-3 in modulating tumor growth and immunosuppression
within the tumor microenvironment. Oncoimmunology. 7:e14344672018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee JH, Zhang X, Shin BK, Lee ES and Kim
I: Mac-2 binding protein and galectin-3 expression in mucinous
tumors of the ovary: An annealing control primer system and
immunohistochemical study. Pathology. 41:229–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kim MK, Sung CO, Do IG, Jeon HK, Song TJ,
Park HS, Lee YY, Kim BG, Lee JW and Bae DS: Overexpression of
galectin-3 and its clinical significance in ovarian carcinoma. Int
J Clin Oncol. 16:352–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Brustmann H: Epidermal growth factor
receptor expression in serous ovarian carcinoma: An
immunohistochemical study with galectin-3 and cyclin D1 and
outcome. Int J Gynecol Pathol. 27:380–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lu H, Liu Y, Wang D, Wang L, Zhou H, Xu G,
Xie L, Wu M, Lin Z and Yu Y: Galectin-3 regulates metastatic
capabilities and chemotherapy sensitivity in epithelial ovarian
carcinoma via NF-κB pathway. Tumour Biol. 37:11469–11477. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kang HG, Kim DH, Kim SJ, Cho Y, Jung J,
Jang W and Chun KH: Galectin-3 supports stemness in ovarian cancer
stem cells by activation of the Notch1 intracellular domain.
Oncotarget. 7:68229–68241. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mirandola L, Yu Y, Cannon MJ, Jenkins MR,
Rahman RL and Nguyen DD: Galectin-3 inhibition suppresses drug
resistance, motility, invasion and angiogenic potential in ovarian
cancer. Gynecol Oncol. 135:573–579. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Eliaz I: The role of galectin-3 as a
marker of cancer and inflammation in a stage IV ovarian cancer
patient with underlying pro-inflammatory comorbidities. Case Rep
Oncol. 6:343–349. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hossein G, Keshavarz M, Ahmadi S and
Naderi N: Synergistic effects of PectaSol-C modified citrus pectin
an inhibitor of galectin-3 and paclitaxel on apoptosis of human
SKOV-3 ovarian cancer cells. Asian Pac J Cancer Prev. 14:7561–7568.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Hossein G, Halvaei S, Heidarian Y,
Dehghani-Ghobadi Z, Hassani M, Hosseini H, Naderi N and Sheikh
Hassani S: Pectasol-C modified citrus pectin targets
galectin-3-induced STAT3 activation and synergize paclitaxel
cytotoxic effect on ovarian cancer spheroids. Cancer Med.
8:4315–4329. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cai G, Ma X, Chen B, Huang Y, Liu S, Yang
H and Zo W: Galectin-3 induces ovarian cancer cell survival and
chemoresistance via TLR4 signalingactivation. Tumour Biol.
37:11883–11891. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wang D, You D and Li L: Galectin-3
regulates chemotherapy sensitivity in epithelial ovarian carcinoma
via regulating mitochondrial function. J Toxicol Sci. 44:47–56.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bieg D, Sypniewski D, Nowak E and Bednarek
I: Morin decreases galectin-3 expression and sensitizes ovarian
cancer cells to cisplatin. Arch Gynecol Obstet. 298:1181–1194.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bieg D, Sypniewski D, Nowak E and Bednarek
I: MiR-424-3p suppresses galectin-3 expression and sensitizes
ovarian cancer cells to cisplatin. Arch Gynecol Obstet.
299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kaur M, Kaur T, Kamboj S and Singh J:
Roles of galectin-7 in cancer. Asian Pac J Cancer Prev. 17:455–461.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Menkhorst E, Griffiths M, van Sinderen M,
Rainczuk K, Niven K and Dimitriadis E: Galectin-7 is elevated in
endometrioid (type I) endometrial cancer and promotes cell
migration. Oncol Lett. 16:4721–4728. 2018.PubMed/NCBI
|
|
72
|
Chou F, Chen H, Kuo C and Sytwu H: Role of
galectins in tumors and in clinical immunotherapy. Int J Mol Sci.
19:430–441. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Johannes L, Jacob R and Leffler H:
Galectins at a glance. J Cell Sci. 131:jcs2088842018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Labrie M, Vladoiu MC, Grosset A, Gaboury L
and St-Pierre Y: Expression and functions of galectin-7 in ovarian
cancer. Oncotarget. 5:7705–7721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Higareda-Almaraz JC, Ruiz-Moreno JS,
Klimentova J, Barbieri D, Salvador-Gallego R, Ly R,
Valtierra-Gutierrez IA, Dinsart C, Rabinovich GA, Stulik J, et al:
Systems-level effects of ectopic galectin-7 reconstitution in
cervical cancer and its microenvironment. BMC Cancer. 16:680–692.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
St-Pierre Y: Towards a better
understanding of the relationships between Galectin-7, p53 and
MMP-9 during cancer progression. Biomolecules. 11:8792021.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Guo JP and Li XG: Galectin-7 promotes the
invasiveness of human oral squamous cell carcinoma cells via
activation of ERK and JNK signaling. Oncol Lett. 13:1919–1924.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Krześlak A: Akt kinase: A key regulator of
metabolism and progression of tumors. Postepy Hig Med Dosw
(Online). 64:490–503. 2010.(In Polish). PubMed/NCBI
|
|
79
|
Kim HJ, Jeon HK, Lee JK, Sung CO, Do IG,
Choi CH, Kim TJ, Kim BG, Bae DS and Lee JW: Clinical significance
of galectin-7 in epithelial ovarian cancer. Anticancer Res.
33:1555–1561. 2013.PubMed/NCBI
|
|
80
|
Bibens-Laulan N and St-Pierre Y:
Intracellular galectin-7 expression in cancer cells results from an
autocrine transcriptional mechanism and endocytosis of
extracellular galectin-7. PLoS One. 12:e01871942017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Elola MT, Ferragut F, Cárdenas Delgado VM,
Nugnes LG, Gentilini L, Laderach D, Troncoso MF, Compagno D,
Wolfenstein-Todel C and Rabinovich GA: Expression, localization and
function of galectin-8, a tandem-repeat lectin, in human tumors.
Histol Histopathol. 29:1093–1105. 2014.PubMed/NCBI
|
|
82
|
Zick Y, Eisenstein M, Goren RA, Hadari YR,
Levy Y and Ronen D: Role of galectin-8 as a modulator of cell
adhesion and cell growth. Glycoconj J. 19:517–526. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Troncoso MF, Ferragut F, Bacigalupo ML,
Cárdenas Delgado VM, Nugnes LG, Gentilini L, Laderach D,
Wolfenstein-Todel C, Compagno D, Rabinovich GA and Elola MT:
Galectin-8: A matricellular lectin with key roles in angiogenesis.
Glycobiology. 10:907–914. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Elola MT, Wolfenstein-Todel C, Troncoso
MF, Vasta GR and Rabinovich GA: Galectins: Matricellular
glycan-binding proteins linking cell adhesion, migration, and
survival. Cell Mol Life Sci. 64:1679–1700. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Levy Y, Arbel-Goren R, Hadari YR, Eshhar
S, Ronen D, Elhanany E, Geiger B and Zick Y: Galectin-8 functions
as a matricellular modulator of cell adhesion. J Biol Chem.
276:31285–31295. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Troncoso MF, Elola MT, Croci DO and
Rabinovich GA: Integrating structure and function of
‘tandem-repeat’ galectins. Front Biosci (Schol Ed). 4:864–887.
2012.PubMed/NCBI
|
|
87
|
Tribulatti MV, Carabelli J, Prato CA and
Campetella O: Galectin-8 in the onset of the immune response and
inflammation. Glycobiology. 30:134–142. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ferragut F, Cagnoni AJ, Colombo LL,
Sánchez Terrero C, Wolfenstein-Todel C, Troncoso MF, Vanzulli SI,
Rabinovich GA, Mariño KV and Elola MT: Dual knockdown of Galectin-8
and its glycosylated ligand, the activated leukocyte cell adhesion
molecule (ALCAM/CD166), synergistically delays in vivo breast
cancer growth. Biochim Biophys Acta Mol Cell Res. 1866:1338–1352.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Fan J, Tang X, Wang Q, Zhang Z, Wu S, Li
W, Liu S, Yao G, Chen H and Sun L: Mesenchymal stem cells alleviate
experimental autoimmune cholangitis through immunosuppression and
cytoprotective function mediated by galectin-9. Stem Cell Res Ther.
9:237–349. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhou X, Sun L, Jing D, Xu G, Zhang J, Lin
L, Zhao J, Yao Z and Lin H: Galectin-9 expression predicts
favorable clinical outcome in solid tumors: A systematic review and
meta-analysis. Front Physiol. 9:4522018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lahm H, André S, Hoeflich A, Fischer JR,
Sordat B, Kaltner H, Wolf E and Gabius HJ: Comprehensive galectin
fingerprinting in a panel of 61 human tumor cell lines by RT-PCR
and its implications for diagnostic and therapeutic procedures. J
Cancer Res Clin Oncol. 127:375–386. 2001. View Article : Google Scholar : PubMed/NCBI
|
